Logo
x

Search category

Subscribe Now

Henlius

Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma

Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma

  • September 25, 2023
Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at ASCO 2023

Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at A...

  • June 8, 2023
Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

  • March 23, 2023
Henlius Reports the US FDA Acceptance of BLA for Proposed Biosimilar Trastuzumab HLX02

Henlius Reports the US FDA Acceptance of BLA for Proposed Biosimilar Trastuzumab HLX02

  • February 16, 2023
Henlius' Hansizhuang (serplulimab) Receives the NMPA’s Approval as 1L Treatment of Extensive Stage Small Cell Lung Cancer

Henlius' Hansizhuang (serplulimab) Receives the NMPA’s Approval as 1L Treatment of Extensive Stage Small Cell Lung Cancer

  • January 17, 2023
Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US

Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US

  • December 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.